The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: Activation of glucagon-like peptide-1 (GLP-1) receptors improves insulin sensitivity and induces vasodilatation and diuresis. AC3174 is a peptide analogue with pharmacologic properties similar to the GLP-1 receptor agonist, exenatide. Hypothetically, chronic AC3174 treatment could attenuate salt-induced hypertension, cardiac morbidity, insulin resistance, and renal dysfunction in Dahl salt-sensitive (DSS) rats. Methods: DSS rats were fed low salt (LS, 0.3% NaCl) or high salt (HS, 8% NaCl) diets. HS rats were treated with vehicle, AC3174 (1.7 pmol/kg/min), or GLP-1 (25 pmol/kg/min) for 4 weeks via subcutaneous infusion. Other HS rats received captopril (150 mg/kg/day) or AC3174 plus captopril. Results: HS rat survival was improved by all treatments except GLP-1. Systolic blood pressure (SBP) was lower in LS rats and in GLP-1, AC3174, captopril, or AC3174 plus captopril HS rats than in vehicle HS rats (p < 0.05). AC3174 plus captopril attenuated the deleterious effects of high salt on posterior wall thickness, LV mass, and the ratio of LV mass to body weight (P ≤ 0.05). In contrast, GLP-1 had no effect on these cardiovascular parameters. All treatments reduced LV wall stress. GLP-1, AC3174, captopril, or AC3174 plus captopril normalized fasting insulin and HOMA-IR (P ≤ 0.05). AC3174, captopril, or AC3174 plus captopril improved renal function (P ≤ 0.05). Renal morphology in HS rats was associated with extensive sclerosis. Monotherapy with AC3174, captopril, or GLP-1 attenuated renal damage. However, AC3174 plus captopril produced the most effective improvement. Conclusions: Thus, AC3174 had antihypertensive, cardioprotective, insulin-sensitizing, and renoprotective effects in the DSS hypertensive rat model. Furthermore, AC3174 improved animal survival, an effect not observed with GLP-1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence, Awareness, Treatment, and Control of Hypertension Among United States Adults 1999–2004
Ong, K. L., Cheung, B. M. Y., Man, Y. B., Lau, C. P., & Lam, K. S. L. (2007) · Hypertension · doi:10.1161/01.hyp.0000252676.46043.18 · Cited by 1,395 · cited 1×
“Congestive heart failure with left ventricular (LV) dysfunction is often found in patients with hypertension [ 2-6 ].”
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 1×
“Intravenous infusion of GLP-1 in patients with acute myocardial infarction for 72 hours after successful angioplasty reportedly improved cardiac function [10].”
Glucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men
Gutzwiller, J.-P., Tschopp, S., Bock, A., Zehnder, C. E., Huber, A. R., Kreyenbuehl, M., Gutmann, H., Drewe, J., Henzen, C., Goeke, B., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031403 · Cited by 442
Blonde, L., Klein, E. J., Han, J., Zhang, B., Mac, S. M., Poon, T. H., Taylor, K. L., Trautmann, M. E., Kim, D. D., & Kendall, D. M. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00602.x · Cited by 416 · cited 1×
“In an open-label, 82-week study, exenatide reduced mean diastolic BP and improved lipid profiles [22].”
Moretto, T. J., Milton, D. R., Ridge, T. D., MacConell, L. A., Okerson, T., Wolka, A. M., & Brodows, R. G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.006 · Cited by 350 · cited 1×
“In a 24-week clinical trial, exenatide reduced mean systolic and diastolic BP in contrast to non-significant BP changes in the placebo arm [23].”
Exenatide once weekly for the treatment of type 2 diabetes
Malone, J., Trautmann, M., Wilhelm, K., Taylor, K., & Kendall, D. M. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902766802 · Cited by 55
Cited by
Röhrborn, D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00386 · Cited by 440
Effects of glucagon-like peptide-1 receptor agonists on renal function
Filippatos, T. D., & Elisaf, M. S. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i5.190 · Cited by 97
Zhao, T. C. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-90 · Cited by 45
Yaribeygi, H., Farrokhi, F. R., Abdalla, M. A., Sathyapalan, T., Banach, M., Jamialahmadi, T., & Sahebkar, A. (2021) · Journal of Diabetes Research · doi:10.1155/2021/6518221 · Cited by 31
Exendin-4 increases oxygen consumption and thermogenic gene expression in muscle cells
Choung, J.-S., Lee, Y.-S., & Jun, H.-S. (2017) · Journal of Molecular Endocrinology · doi:10.1530/jme-16-0078 · Cited by 31
Metadata
- Authors
- Liu, Q., Adams, L., Broyde, A., Fernandez, R., Baron, A. D., & Parkes, D. G.
- Venue
- Cardiovascular Diabetology
- Published
- 2010-08-03
- Volume
- 9
- Issue
- 1
- Pages
- 32-32
- ISSN
- 1475-2840 (ISSN-L)
- OpenAlex
- W2120431951
- Cited by
- 66
- References
- 6
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats. https://app.cochat.ai/papers/10.1186/1475-2840-9-32
- The paper
- Liu, Q., Adams, L., Broyde, A., Fernandez, R., Baron, A. D., & Parkes, D. G. (2010). The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats. Cardiovascular Diabetology. https://doi.org/10.1186/1475-2840-9-32
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.